Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) Profit After Tax (2016 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed Profit After Tax for 16 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 1.81% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.0 million through Dec 2025, down 9.13% year-over-year, with the annual reading at -$6.0 million for FY2025, 9.13% down from the prior year.
  • Profit After Tax for Q4 2025 was -$1.9 million at Creative Medical Technology Holdings, down from -$1.2 million in the prior quarter.
  • The five-year high for Profit After Tax was $27.8 million in Q1 2021, with the low at -$6.2 million in Q4 2022.
  • Average Profit After Tax over 5 years is -$385367.0, with a median of -$1.5 million recorded in 2023.
  • Peak annual rise in Profit After Tax hit 643.79% in 2021, while the deepest fall reached 566.91% in 2021.
  • Over 5 years, Profit After Tax stood at -$3.9 million in 2021, then plummeted by 60.39% to -$6.2 million in 2022, then soared by 72.99% to -$1.7 million in 2023, then fell by 10.46% to -$1.9 million in 2024, then decreased by 1.81% to -$1.9 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$1.9 million, -$1.2 million, and -$1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.